Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Asian Pac J Cancer Prev ; 12(3): 699-702, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21627367

RESUMEN

OBJECTIVE: To evaluate pretreatment levels of serum VEGF in locally advanced cervical cancer patients, and assess any association with clinocopathological parameters and response to radiotherapy. METHODS: Patients with histologically proven and diagnosed locally advanced cervical cancer or stages IIB-IVA were included in this study. Blood serum was obtained by peripheral venous puncture about 24 hours before the beginning of radiotherapy. All patients were followed up at one and three month intervals from the last day of the complete treatment for evaluating the responses to radiotherapy. RESULTS: Mean age of the 40 patients was 52.8 ± 11.1 years. Sixty percent were in stage IIB and 90% had squamous cell carcinoma. The median pretreatment level of serum VEGF was 611.3 pg/ml (0.00-4,067 pg/ml). The pretreatment levels of serum VEGF did not correlate with stage (p=0.75), tumor histology (p=0.91), tumor size (p=0.46) or tumor characteristics (p=0.49). Almost all patients received concurrent chemoradiation as a curative treatment, with a complete response found in 94.9%. Values for patients who were completed response was rather lower than in patients with persistent disease, but without statistical significance (581.4 pg/ml vs 759.6 pg/ml, p=0.37). CONCLUSION: Pretreatment levels of serum VEGF do not correlate with clinicopathological factors or response to radiation therapy.


Asunto(s)
Adenocarcinoma/sangre , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Biomarcadores de Tumor/sangre , Carcinoma de Células Escamosas/sangre , Neoplasias del Cuello Uterino/sangre , Factor A de Crecimiento Endotelial Vascular/sangre , Adenocarcinoma/terapia , Adulto , Anciano , Braquiterapia , Carboplatino/administración & dosificación , Carcinoma de Células Escamosas/terapia , Cisplatino/administración & dosificación , Terapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Tasa de Supervivencia , Resultado del Tratamiento , Neoplasias del Cuello Uterino/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA